comparemela.com
Home
Live Updates
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 : comparemela.com
Vincerx Pharma Reports Fourth Quarter and Full Year 2023
VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a...
Related Keywords
United States ,
California ,
Germany ,
Palo Alto ,
American ,
Ahmed Hamdy ,
Gabriela Jairala ,
Zheng Chen ,
Totyana Simien ,
Raquel Izumi ,
Exchange Commission ,
Vincerx Pharma Inc ,
American Association Of Cancer Research ,
Nasdaq ,
Securities Exchange ,
European Hematology Association ,
National Institutes Of Health ,
Vincerxpharma Inc ,
Hematology Association ,
Annual Meeting ,
Cancer Research ,
Vincerx Pharma ,
Chief Executive ,
Chief Operations Officer ,
National Institutes ,
Exploring Innovative Strategies ,
Structural Modification ,
Therapeutic Advancements ,
Investors Page ,
Induces Complete Regression ,
Cancer Research Communications ,
Securities Act ,
Securities Exchange Act ,
Consolidated Statements ,
Nasdaq Vinc ,
Nc ,
Inc ,
comparemela.com © 2020. All Rights Reserved.